Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kura Oncology (KURA)

Kura Oncology (KURA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,910,493
  • Shares Outstanding, K 56,708
  • Annual Sales, $ 0 K
  • Annual Income, $ -63,140 K
  • 60-Month Beta 2.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.67
Trade KURA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.47
  • Number of Estimates 6
  • High Estimate -0.42
  • Low Estimate -0.61
  • Prior Year -0.39
  • Growth Rate Est. (year over year) -20.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.10 +15.77%
on 11/04/20
40.62 -17.06%
on 11/13/20
+2.31 (+7.36%)
since 11/02/20
3-Month
22.67 +48.61%
on 09/04/20
40.62 -17.06%
on 11/13/20
+9.58 (+39.73%)
since 09/02/20
52-Week
6.35 +430.55%
on 03/19/20
40.62 -17.06%
on 11/13/20
+18.21 (+117.71%)
since 12/02/19

Most Recent Stories

More News
Kura Oncology to Host Virtual Investor Event on December 5, 2020

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting...

KURA : 33.69 (-1.20%)
Kura Oncology: 3Q Earnings Snapshot

SAN DIEGO (AP) _ Kura Oncology Inc. (KURA) on Thursday reported a loss of $23.8 million in its third quarter.

KURA : 33.69 (-1.20%)
Kura Oncology Reports Third Quarter 2020 Financial Results

- Preliminary data from first-in-human trial of menin inhibitor KO-539 accepted for oral presentation at ASH -

KURA : 33.69 (-1.20%)
Kura Oncology, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Kura Oncology, Inc. (NASDAQ:KURA) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 5, 2020 at 8:00...

KURA : 33.69 (-1.20%)
Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is...

KURA : 33.69 (-1.20%)
Kura Oncology to Report Third Quarter 2020 Financial Results

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter...

KURA : 33.69 (-1.20%)
Kura Oncology Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Kα Inhibitor in Head and Neck Squamous Cell Carcinoma

- Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of HNSCC -

KURA : 33.69 (-1.20%)
Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract reporting...

KURA : 33.69 (-1.20%)
4 Biotech Stocks Showing Strength During the Market Selloff in September

While the market has mainly sold-off this month, four biotech stocks have showed strength in anticipation of successful drug candidates: Arena Pharmaceuticals (ARNA), Fate Therapeutics (FATE), Kura Oncology...

ARNA : 65.68 (-0.65%)
FATE : 60.53 (+0.51%)
KURA : 33.69 (-1.20%)
STOK : 46.02 (-6.65%)
Kura Oncology to Participate in Two Upcoming Investor Conferences

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D.,...

KURA : 33.69 (-1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Key Turning Points

2nd Resistance Point 35.00
1st Resistance Point 34.34
Last Price 33.69
1st Support Level 33.06
2nd Support Level 32.44

See More

52-Week High 40.62
Last Price 33.69
Fibonacci 61.8% 27.53
Fibonacci 50% 23.48
Fibonacci 38.2% 19.44
52-Week Low 6.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar